NGM Bio’s IPO Raises $107M as NASH Drug Continues Clinical Testing

NGM Bio’s IPO Raises $107M as NASH Drug Continues Clinical Testing

Source: 
Xconomy
snippet: 

So far this year, NGM Biopharmaceuticals has licensed a drug to Merck, extended a research agreement with that partner, and laid the groundwork to continue mid-stage testing of its wholly-owned lead compound. Now it can add a $107 million IPO to the list.